The use of 37 °C hypoxia in our in vitro model in the present study may also explain the discrepancy in protection found between the STS pre-treatment combined with the hypoxic treatment group and its corresponding group in our in vivo model, where ischemia occurred at 4 °C. This evidence concerns the gene STS and ischemia.